The estimated Net Worth of Hans Mueller is at least $4.3 ezer dollars as of 24 November 2009. Hans Mueller owns over 4,000 units of Idera Pharmaceuticals stock worth over $4,300 and over the last 17 years Hans sold IDRA stock worth over $0.
Hans has made over 4 trades of the Idera Pharmaceuticals stock since 2009, according to the Form 4 filled with the SEC. Most recently Hans bought 4,000 units of IDRA stock worth $20,400 on 24 November 2009.
The largest trade Hans's ever made was buying 4,000 units of Idera Pharmaceuticals stock on 24 November 2009 worth over $20,400. On average, Hans trades about 1,000 units every 20 days since 2008. As of 24 November 2009 Hans still owns at least 10,000 units of Idera Pharmaceuticals stock.
You can see the complete history of Hans Mueller stock trades at the bottom of the page.
Hans's mailing address filed with the SEC is 1802 CHESTER HOLLOW LANE, , WEST CHESTER, PA, 19382.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... és Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: